- Home
- NIU vs DMAC Comparison
NIU vs DMAC Comparison
Compare NIU & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIU
- DMAC
- Stock Information
- Founded
- NIU 2014
- DMAC 2000
- Country
- NIU China
- DMAC United States
- Employees
- NIU N/A
- DMAC N/A
- Industry
- NIU Auto Manufacturing
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- NIU Consumer Discretionary
- DMAC Health Care
- Exchange
- NIU Nasdaq
- DMAC Nasdaq
- Market Cap
- NIU 216.7M
- DMAC 178.0M
- IPO Year
- NIU 2018
- DMAC N/A
- Fundamental
- Price
- NIU $3.51
- DMAC $3.63
- Analyst Decision
- NIU
- DMAC Strong Buy
- Analyst Count
- NIU 0
- DMAC 2
- Target Price
- NIU N/A
- DMAC $8.00
- AVG Volume (30 Days)
- NIU 1.2M
- DMAC 112.1K
- Earning Date
- NIU 08-11-2025
- DMAC 08-06-2025
- Dividend Yield
- NIU N/A
- DMAC N/A
- EPS Growth
- NIU N/A
- DMAC N/A
- EPS
- NIU N/A
- DMAC N/A
- Revenue
- NIU $477,578,753.00
- DMAC N/A
- Revenue This Year
- NIU $41.32
- DMAC N/A
- Revenue Next Year
- NIU $24.38
- DMAC N/A
- P/E Ratio
- NIU N/A
- DMAC N/A
- Revenue Growth
- NIU 26.51
- DMAC N/A
- 52 Week Low
- NIU $1.65
- DMAC $2.14
- 52 Week High
- NIU $4.90
- DMAC $6.82
- Technical
- Relative Strength Index (RSI)
- NIU 49.77
- DMAC 46.56
- Support Level
- NIU $3.12
- DMAC $4.02
- Resistance Level
- NIU $3.93
- DMAC $4.17
- Average True Range (ATR)
- NIU 0.21
- DMAC 0.25
- MACD
- NIU 0.01
- DMAC -0.04
- Stochastic Oscillator
- NIU 48.15
- DMAC 37.89
About NIU Niu Technologies
Niu Technologies designs, manufactures and sells high-performance electric motorcycles, scooters, bicycles, and kick-scooters. The company has a product portfolio consisting of electric motorcycle, mopeds and bicycle series, including the NQi, MQi, UQi, F series, and others, and micro-mobility series, including the kick-scooter series KQi and the e-bike series BQi. The company's principal operations and geographic markets are predominantly in the People's Republic of China. It also generates revenue from Europe and other regions.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.